期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

超小剂量的地西他滨联合CAG方案治疗中高危骨髓增生异常综合征及难治性白血病的效果分析 被引量：13

Analysis of Ultra Low Dose Decitabine Combined With CAG Regimen in the Treatment of High-risk Myelodysplastic Syndrome and Abnormal Synthesis of Refractory Leukemia Effect
下载PDF
导出
摘要 目的分析超小剂量的地西他滨联合CAG方案治疗中高危骨髓增生异常综合征（MDS）及难治性白血病（AML）的效果。方法选取我院2012年5月-2014年5月收治的120例MDS或AML患者作为研究对象,随机分成对照组（60例）和观察组（60例）。对照组采取单用超小剂量的地西他滨治疗,观察组采取超小剂量的地西他滨联合CAG方案治疗。结果观察组患者的治疗总有效率及总生存时间等观察指标均优于对照组（P〈0.05）。结论超小剂量的地西他滨联合CAG方案治疗中高危骨髓增生异常综合征及难治性白血病的效果显著。 Objective Analysis of ultra small doses of land west of the CAG combination regimen for high-risk myelodysplastic syndrome（MDS） and the effect of refractory leukemia（AML）. Methods 120 cases of MDS and AML patients as the research object from May 2012 to May 2014, randomly divided into control group（60 cases） and observation group（60 cases）. Control group take the use ultra small doses of his west marina treatment, observation group adopt ultra small doses of west the CAG regimen for combination. Results The treatment of patients with observation group total effective rate and total survival time observation indexes were significantly better than that of control group（P〈0.05）. Conclusion The small doses of land west of the CAG combination regimen for high-risk myelodysplastic syndrome and refractory leukemia effect is remarkable.
作者 王萍
机构地区 河南省驻马店市中心医院
出处 《中国继续医学教育》 2016年第5期146-147,共2页 China Continuing Medical Education
关键词 骨髓增生异常综合征 难治性白血病 地西他滨 CAG方案 效果 Myelodysplastic syndrome Refractory leukemia Decitabine CAG plan Effect
分类号 R733 [医药卫生—肿瘤]
  • 相关文献

参考文献9

二级参考文献93

  • 1Nimer SD. Myelodysplastic syndromes. Blood, 2008, 111:4841-4851.
  • 2Plimaek ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoiefic malignancies. Leuk Lymphoma, 2007, 48: 1472-1480.
  • 3Solomon PR, Munirajan AK, Tsuchida N, et al. Promoter hypermethylation analysis in myelodysplastic syndromes: diagnostic&prognostic implication. Indian J Med Res, 2008, 127:52- 57.
  • 4Issa JP,Garcia-Manero G,Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'- deoxycytidine(decitabine) in hematopoietic malignancies.Blood, 2004, 103:1635-1640.
  • 5Mund C,Hackanson B,Stresemann C,et al.Characterization of DNA demethylation effects induced by 5-aza-2'-deoxyeytidine in patients with myelodysplastic syndrome.Cancer Res, 2005, 65:7086-7090.
  • 6张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2006:279-281.
  • 7Saba HI.Decitabine in the treatment of myelodysplastic syndromes[J].Ther Clin Risk Manag,2007,3:807-817.
  • 8Santini V,Kantarjian HM,Issa JP.Changes in DNA methylation in neoplasia:pathophysiology and therapeutic implications[J].Ann Intern Med,2001,134:573-586.
  • 9Kantarjian H,Oki Y,Garcia-Manero G,et al.Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood,2007,109:52-57.
  • 10Chowdhury S,Seropian S,Marks PW.Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia[J].Am J Hematol,2009,84:599-600.

共引文献174

同被引文献107

  • 1蔡成森,孙爱宁,仇惠英,何广胜,唐晓文,金正明,傅琤琤,吴德沛.地西他滨单药及联合AAG方案治疗初治急性髓系白血病的临床观察[J].中华临床医师杂志（电子版）,2012,6(19):6092-6094. 被引量：13
  • 2钱思轩,李建勇,沈云峰,蒋元强,陆化,吴汉新,徐卫,程蕴琳,盛瑞兰.CAG预激方案治疗老年人急性髓细胞白血病的临床观察[J].中华老年医学杂志,2007,26(4):248-250. 被引量：39
  • 3Reece- Smith AM,MacGoey P,Shah MA,et al. A multi- centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal turnouts in the post-imatinib era [J]. European Journal of Surgical Oncology the Journal of the European Society of Surgical Oncology & the British Association of Surgical Oncology, 2012,38(6) :484-489.
  • 4Haase D, Germing U, Schanz J,et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 pa- tients [J]. Blood, 2007,110(13) : 4385-4395.
  • 5Bernaseoni P. Molecular pathways in myelodysplastic syn- dromes and acute myeloid leukemia:relationships and dis- tinctions-a review [J]. British Journal of Haematology,2008, 142 (5) : 695-708.
  • 6Issa JP,Garciamanero G,Giles FJ,et al. Phase 1 study of low-dose prolonged exposure schedules of the hy- pomethylating agent 5-aza-2"-deoxycytidine(decitabine) in hematopoietic malignancies [J]. Blood,2004,103 (5) : 1635 - 1640.
  • 7Kantarjian H,Issa JP,Rosenfeld CS,et al. Decitabine improves patient outcomes in myelodysplastic syn- dromes: results of a phase III randomized study [J]. Cancer, 2006,106(8) : 1794-1803.
  • 8Steensma DP, Baer MR, Slack JL, et al. Multicenter study of deeitabine administered daily for 5 days every 4 weeks to adults with myelodysplastie syndromes:the al- ternative dosing for outpatient treatment(ADOPT)trial [J]. Journal of Clinical Oneology Official Journal of the Ameriean Society of Clinical Oneology,2009,27 (23):3842-3848.
  • 9Garcia-Manero G, Jabbour E,Borthakur G, et al. Ran- domized open-label phase Ⅱ study of decitabine in pa- tients with low-or intermediate-risk myelodysplasticsyn- dromes [J]. Journal of Clinical Oncology,2013,31 (20): 2548-2553.
  • 10Garg R,Faderl S,Garcia-Manero G,et al. Phase Ⅱ study of rabbit anti-thymocyte globulin, cyclosporine and gran- ulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplasticsyndrome [J]. Leukemia,2009, 23(7) : 1297-1302.

引证文献13

二级引证文献108

中国继续医学教育
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部